stoxline Quote Chart Rank Option Currency Glossary
Ensysce Biosciences, Inc. (ENSC)
0.9833  0.005 (0.48%)    12-07 15:57
Open: 0.9798
High: 1
Volume: 22,065
Pre. Close: 0.9786
Low: 0.965
Market Cap: 3(M)
Technical analysis
2023-12-07 4:20:22 PM
Short term     
Mid term     
Targets 6-month :  1.41 1-year :  1.74
Resists First :  1.21 Second :  1.49
Pivot price 0.91
Supports First :  0.76 Second :  0.63
MAs MA(5) :  0.95 MA(20) :  0.89
MA(100) :  1.48 MA(250) :  3.92
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  28.1 D(3) :  26.2
RSI RSI(14): 50.3
52-week High :  18.36 Low :  0.76
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ ENSC ] has closed below upper band by 28.8%. Bollinger Bands are 32.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1 - 1.01 1.01 - 1.01
Low: 0.96 - 0.96 0.96 - 0.96
Close: 0.98 - 0.98 0.98 - 0.99
Company Description

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California.

Headline News

Fri, 01 Dec 2023
Should You Buy Ensysce Biosciences Inc (ENSC) Stock Friday Morning? - InvestorsObserver

Tue, 28 Nov 2023
Ensysce Biosciences and OncoZenge Announce Letter of Intent for the Co-development of BupiZenge(TM) in the ... - Yahoo Finance

Thu, 16 Nov 2023
Ensysce Biosciences Announces Enrollment Completion for PF614-201 Clinical Study - Ensysce Biosciences (N - Benzinga

Tue, 24 Oct 2023
Ensysce Biosciences Secures $1.7 Million Convertible Note Financing - Yahoo Finance

Wed, 18 Oct 2023
Is Ensysce Biosciences Inc (ENSC) Stock at the Top of the Biotechnology Industry? - InvestorsObserver

Tue, 17 Oct 2023
Premarket Mover: Ensysce Biosciences Inc (ENSC) Down 11.41% - InvestorsObserver

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 3 (M)
Shares Float 3 (M)
Held by Insiders 4.3 (%)
Held by Institutions 5.9 (%)
Shares Short 68 (K)
Shares Short P.Month 23 (K)
Stock Financials
EPS -1.87
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.51
Profit Margin 0 %
Operating Margin -621.9 %
Return on Assets (ttm) -149.5 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 55.9 %
Gross Profit (p.s.) 0
Sales Per Share 1
EBITDA (p.s.) 0
Qtrly Earnings Growth 0 %
Operating Cash Flow -12 (M)
Levered Free Cash Flow -9 (M)
Stock Valuations
PE Ratio -0.53
PEG Ratio 0
Price to Book value 1.89
Price to Sales 0.98
Price to Cash Flow -0.26
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android